NoreenRothHenigMD
Pulmonology • San Francisco, CACritical Care Medicine
Sr. Director, Cardiopulmonary Medical Affairs
Dr. Henig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2351 Clay St
#501
San Francisco, CA 94115Phone+1 415-923-3421Fax+1 415-600-1414
Education & Training
University of WashingtonFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1998
University of California (San Francisco)Residency, Internal Medicine, 1992 - 1995
Albert Einstein College of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1994 - 2026
Clinical Trials
- Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) Start of enrollment: 2020 Mar 12
Publications & Presentations
PubMed
- 42 citationsAntisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosisPavel Drevinek, Tacjana Pressler, Marco Cipolli, Kris De Boeck, Carsten Schwarz
Journal of Cystic Fibrosis. 2020-01-01 - 39 citationsAntisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisIsabelle Sermet-Gaudelus, John P. Clancy, David P. Nichols, Jerry A. Nick, Kris De Boeck
Journal of Cystic Fibrosis. 2019-07-01 - 106 citationsPulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restrictionGanesh Raghu, Steven D. Nathan, Juergen Behr, Kevin K. Brown, Jim J. Egan
The European Respiratory Journal. 2015-08-06
Press Mentions
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 1st, 2023- Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus NephritisJune 27th, 2022
- Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus NephritisNovember 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
